|
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 854950
Online Users : 900
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/3318
|
Title: | Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of 188Re-DXR-liposome in C26 colon carcinoma ascites mice model |
Other Titles: | Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of Re-188-DXR-liposome in C26 colon carcinoma ascites mice model |
Authors: | Chen, LC;Chang, CH;Yu, CY;Chang, YJ;Wu, YH;Lee, WC;Yeh, CH;Lee, TW;Ting, G |
Contributors: | National Institute of Cancer Research |
Abstract: | The pharmacokinetics and internal radionuclide therapy of intraperitoneally administrated 188Re-N,N-bis(2-mercaptoethyl)-N?,N?-diethylethylenediamine (BMEDA)-labeled pegylated liposomal doxorubicin (188Re-DXR-liposome) were investigated in the C26 murine colon carcinoma ascites mouse model. After intraperitoneal administration of the nanotargeted bimodality 188Re-DXR-liposome, the ascites and tumor accumulation of the radioactivity were observed, the levels of radioactivity within the ascites were maintained at relatively higher levels before 48 h and the levels of radioactivity in the tumor were maintained at steady levels after 4 h. The AUC(o??) of 188Re-DXR-liposome in blood, ascites and tumor was 9.3-, 4.2- and 4.7-fold larger than that of 188Re-BMEDA, respectively. The maximum tolerated dose of intraperitoneally administrated 188Re-DXR-liposome was determined in normal BALB/c mice. The survival, tumor and ascites inhibition of mice after 188Re-DXR-liposome (22.2 MBq of 188Re, 5 mg/kg of DXR) treatment were evaluated. Consequently, radiochemotherapeutics of 188Re-DXR-liposome attained better survival time, tumor and ascites inhibition (decreased by 49% and 91% at 4 days after treatment; P<.05) in mice than radiotherapeutics of 188Re-liposome or chemotherapeutics of Lipo-Dox did. Therefore, intraperitoneal administration of novel 188Re-DXR-liposome could provide a benefit and promising strategy for delivery of passive nanotargeted bimodality radiochemotherapeutics in oncology applications. |
Date: | 2008-11 |
Relation: | Nuclear Medicine and Biology. 2008 Nov;35(8):883-893. |
Link to: | http://dx.doi.org/10.1016/j.nucmedbio.2008.09.005 |
JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0969-8051&DestApp=IC2JCR |
Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000261603300009 |
Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=56249084276 |
Appears in Collections: | [其他] 期刊論文
|
Files in This Item:
File |
Description |
Size | Format | |
SCP56249084276.pdf | | 712Kb | Adobe PDF | 632 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|